Safety and Immunogenicity of a Modified Self-Amplifying Ribonucleic Acid (saRNA) Vaccine Encoding SARS-CoV-2 Spike Glycoprotein in SARS-CoV-2 Seronegative and Seropositive Ugandan Individuals

Safety and Immunogenicity of a Modified Self-Amplifying Ribonucleic Acid (saRNA) Vaccine Encoding SARS-CoV-2 Spike Glycoprotein in SARS-CoV-2 Seronegative and Seropositive Ugandan Individuals

Background: The COVID-19 pandemic highlighted the need for innovative vaccine platforms that elicit durable immunity. Self-amplifying RNA (saRNA) vaccines offer rapid production and dose-sparing advantages over traditional mRNA platforms. In Uganda’s first SARS-CoV-2 vaccine trial (NCT04934111), we...

Full description

Saved in:
Bibliographic Details
Main Authors: Jonathan Kitonsa, Jennifer Serwanga, Hannah M. Cheeseman, Andrew Abaasa, Jane Frances Lunkuse, Eugene Ruzagira, Laban Kato, Florence Nambaziira, Gerald Kevin Oluka, Ben Gombe, Sembera Jackson, Joseph Katende Ssebwana, Leon R. McFarlane, Sarah Joseph, Benjamin F. Pierce, Robin J. Shattock, Pontiano Kaleebu
Format: Article
Language:English
Published: MDPI AG 2025-05-01
Series:Vaccines
Subjects:
self-amplifying RNA (saRNA) vaccine
SARS-CoV-2 immunogenicity
COVID-19 vaccination in Africa
neutralising antibody responses
spike-specific IgG antibodies
vaccine safety and reactogenicity
Online Access:https://www.mdpi.com/2076-393X/13/6/553
Tags: Add Tag
No Tags, Be the first to tag this record!
Login for hold and recall information

Internet

https://www.mdpi.com/2076-393X/13/6/553

Similar Items